Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs WD 40 Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while WD 40 Company trades at $231.66 (market cap $3.13B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 9.5× WD 40 Company's market cap, and WD 40 Company pays a 1.75% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WDFC | |
|---|---|---|
Market Cap | $29.60B | $3.13B |
Sector | Health | Technology |
52-Week High | $491.22 | $264.91 |
52-Week Low | $205.48 | $187.52 |
Enterprise Value | $27.56B | $3.18B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
WDFC trades at $232.3, down 0.94% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $2.33 per share, beating estimates, but faces gross margin pressure from input costs. Revenue grew to $675 million in 2026, though net income slightly declined to $89 million. A dividend of $1.02 per share is scheduled for payment on July 31, 2026.
The outlook is mixed: solid brand strength and cash flow support stability, but high valuation (P/E 35.39) and margin pressures pose risks. Analyst sentiment is cautious with a hold-heavy consensus. Key opportunities include global market penetration, while risks involve cost inflation and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
